 Home > Active Ingredient News > Antitumor Therapy > J Thorac Oncol: Long-term efficacy of nivolumab + ipilimumab in the treatment of advanced non-small cell lung cancer

J Thorac Oncol: Long-term efficacy of nivolumab + ipilimumab in the treatment of advanced non-small cell lung cancer

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

pearl powder benefits

make non profit

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the CheckMate 227 study, compared with chemotherapy, nivolumab combined with ipilimumab can prolong the total number of patients with non-small cell lung cancer ( NSCLC ) with PD-L1 expression ≥1% Survival (OS; primary endpoint); and in a predetermined descriptive analysis, nivolumab combined with ipilimumab can also extend the overall survival of NSCLC patients with PD-L1<1%

Compared with chemotherapy, nivolumab combined with ipilimumab can prolong the overall survival of NSCLC patients with non-small cell lung cancer ( NSCLC ) whose tumor programmed death ligand 1 (PD-L1) expression is ≥1%

This article reports the results of the CheckMate 227 study, which was followed up for the shortest 4 years

In this study, patients with stage IV or recurrent NSCLC who had not been treated before were randomly assigned (1:1:1) to the nivolumab combined with ipilimumab group, nivolumab group or chemotherapy group (PD- L1≥1%); or be randomly assigned to nivolumab combined with ipilimumab group, nivolumab combined with chemotherapy group or chemotherapy group (PD-L1<1%)

immunity

4-year OS rate of patients in different treatment groups

After a median follow-up of 54.

In short, in the analysis of the results of the CheckMate 227 study with the shortest follow-up of 4 years, nivolumab combined with ipilimumab as the first-line treatment for patients with advanced NSCLC has a long-lasting long-term effect when all patients have stopped immunotherapy for ≥ 2 years.

Nivolumab combined with Ipilimumab as the first-line treatment for patients with advanced NSCLC has a long-lasting long-term effect.

Original source:

Paz-Ares Luis G, Ramalingam Suresh S, Ciuleanu Tudor-Eliade et al.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.